Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

Blackpearl Group oversubscribes raise by $2.5m
Markets

Blackpearl Group oversubscribes raise by $2.5m

The round was upsized to total $12.5m because of interest from investors.

Being AI pushes out Spectrum acquisition close date
Markets

Being AI pushes out Spectrum acquisition close date

The $3.3m deal was expected to close late September.

Ben Moore 10:35am
NZ dollar's wings clipped, RBNZ tipped to go 50bps
Economy

NZ dollar's wings clipped, RBNZ tipped to go 50bps

The kiwi is sliding, but it is more about the greenback than the RBNZ. 

NZ market rises on potential for more Chinese stimulus
Markets Market Close

NZ market rises on potential for more Chinese stimulus

Overnight US bond yields were down.

Graham Skellern 04 Oct 2024